CVSA

CVSA has decisively broken a major support level in a Stage 4 decline, with short EMAs turning down and acting as resistance. The active Support Failure pattern and high-volume breakdown signal accelerating downside, making selling into any relief rally into the declining EMA cluster the preferred execution posture now.

• ↑Revenue rose 4.5% YoY to $487 M; FY26 revenue guidance at $1.93–1.945 B.
• ↑Adjusted EPS expected to grow 19–22% YoY, boosting margins.
• ↓Stock trades ~25% above intrinsic value: $135.55 vs $108.36 fair estimate.